• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Acorda Therapeutics COO resigns

August 19, 2022 By Sean Whooley

Acorda Therapeutics (Nasdaq:ACOR) announced today that Chief Operating Officer Lauren Sabella will resign next month.

Pearl River, New York-based Acorda develops therapies designed to restore function and improve the lives of those with neurological disorders. The therapies are delivered via inhalation through the company’s Arcus pulmonary delivery system.

Sabella’s resignation will be made effective Sept. 30, 2022. She will be working in a strategic advisory role for early-stage biotechnology companies, the company said in a news release. Similarly, when chief of business operations David Lawrence resigned last year, Acorda said he was set to take a leadership position at an early-stage biotechnology company.

“We are grateful for Lauren’s thirteen years of contributions as a member of Acorda’s executive leadership team. Initially, she and her team led the commercial launch of AMPYRA, a novel treatment for multiple sclerosis,” Acorda President and CEO Dr. Ron Cohen said in the release. “The tremendous success of that product allowed Acorda to invest in additional clinical development programs, including INBRIJA for Parkinson’s disease. Lauren has been an outstanding leader at Acorda; we will miss her and wish her a fulfilling next chapter in her career.”

Sabella’s responsibilities will be assumed by two of her current direct reports: SVP of Operations & Strategic Planning Sofia Ali and SVP of Drug Development and Regulatory Affairs Susan Way.

“I am honored to have been part of the Acorda team. I take particular pride in knowing that the FDA-approved products we have brought to market have helped so many people living with multiple sclerosis and Parkinson’s disease,” Sabella said. “I am also proud to have prepared outstanding senior leaders to help guide Acorda’s success moving forward.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals Tagged With: Acorda Therapeutics, Personnel, Personnel Moves

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS